Healthcare / BiotechnologyThailand
$4.20
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-22.7M · quality 46.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
51/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.5B
P/E
10.5x
↓EV/EBITDA
8.7x
↓ROE
5.9%
↑Gross Margin
41.0%
↓Debt/Equity
0.19
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+12.9%
FCF CAGR
+20.8%
FCF margin
7.5%
FCF / Net income
1.34x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.19B · net income $122.4M · FCF $164.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.19B | $2.19B | $1.90B | $1.78B | $1.52B |
| Net Income | $122.4M | $122.4M | $36.6M | $50.8M | $118.9M |
| EBITDA | $307.5M | $307.5M | $185.2M | $205.4M | $235.8M |
| EPS | 0.20 | 0.20 | 0.06 | 0.08 | 0.22 |
| Gross Margin | 41.0% | 41.0% | 37.4% | 37.0% | 40.6% |
| Operating Margin | 8.8% | 8.8% | 3.9% | 6.1% | 11.2% |
| Net Margin | 5.6% | 5.6% | 1.9% | 2.9% | 7.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.19 | 0.19 | 0.20 | 0.21 | 0.28 |
| Current Ratio | 1.80 | 1.80 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $164.2M | $164.2M | $-83.6M | $-22.7M | $93.1M |
| Returns | |||||
| ROE | 5.9% | 5.9% | 1.9% | 2.7% | 6.2% |
| Valuation | |||||
| P/E | 10.50 | 10.50 | — | — | — |
| EV/EBITDA | 8.66 | 8.66 | — | — | — |
| P/B | 1.23 | 1.23 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 15.6% | 15.6% | 6.5% | 16.9% | — |
| EPS Growth | 231.1% | 231.1% | -27.4% | -62.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
22.6%
EPS terminal req.
$0.37
Spread vs growth
208.5%
5Y implied EPS CAGR
17.4%
EPS terminal req.
$0.45
Spread vs growth
213.7%
10Y implied EPS CAGR
13.7%
EPS terminal req.
$0.73
Spread vs growth
217.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+0.0%
Start / end P/E
68.9x → 20.8x
EPS bridge
0.06 → 0.20
Residual
-161.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.